Shortly after leaving the pharmaceutical industry, I was still a current subject matter expert on 21 CFR Part 11, with additional relevant experience in manufacturing quality assurance and regulatory compliance. I was sent as a stringer by an industry trade publication to cover a conference in which a federal quality systems guidance document was discussed.
I attended the one day conference on a press pass for the publication, with the understanding I would report any notable information. I pitched this article based on information presented in the keynote session.